Peng Chun-Wei, Li Yan, Yang Guo-Liang, Xiong Bin, Feng Mao-Hui, Cheng Fu-Lin
Department of Oncology, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Tumor Biological Behaviors & Hubei Cancer Clinical Study Center, Wuhan City, Hubei Province, China.
Hepatogastroenterology. 2010 May-Jun;57(99-100):663-7.
BACKGROUND/AIMS: Gastric cancer (GC) is the leading cause of death in China. Although surgery based comprehensive treatment is the best approach to improve survival, postoperative recurrence is a major problem. This study was aimed to find out the relationship of cancer recurrence with major clinico-pathological factors, with special attention focused on time of recurrence.
Data of 59 recurrences after surgery among 286 GC patients were systemically collected and analyzed. Time of recurrence, the relationship between clinical stages and time of recurrence, and between number of adjuvant chemotherapy cycles and time of recurrence were evaluated.
76.3% (45/59) recurrence happened within 1 year after surgery. Median time to recurrence was 7 months. Most recurrences were locoregional recurrence (57.6%). The differences in time of recurrence among stage I, stage II, stage III and stage IV were statistically not significant (p > 0.05, Kruskal-Wallis Test). There were significant differences among different adjuvant chemotherapy cycles for time to recurrence (p = 0.014, Kruskal-Wallis Test).
Close monitoring and active followup of patients with GC should be conducted over the first 2 years after operation. Adjuvant chemotherapy could prolong recurrence-free survival.
背景/目的:胃癌(GC)是中国主要的死亡原因。尽管以手术为主的综合治疗是提高生存率的最佳方法,但术后复发是一个主要问题。本研究旨在找出癌症复发与主要临床病理因素之间的关系,特别关注复发时间。
系统收集并分析了286例GC患者术后59次复发的数据。评估了复发时间、临床分期与复发时间之间的关系,以及辅助化疗周期数与复发时间之间的关系。
76.3%(45/59)的复发发生在术后1年内。复发的中位时间为7个月。大多数复发为局部区域复发(57.6%)。I期、II期、III期和IV期之间的复发时间差异无统计学意义(p>0.05,Kruskal-Wallis检验)。不同辅助化疗周期的复发时间存在显著差异(p=0.014,Kruskal-Wallis检验)。
术后前2年应对GC患者进行密切监测和积极随访。辅助化疗可延长无复发生存期。